Servo-n HFOV Study: Safety and Performance in Neonates and Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-15

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and performance of High-Frequency Oscillatory Ventilation (HFOV) modes of the Servo-n ventilator in neonates and infants, by using a prospective, observational, single-arm (i.e., non-controlled) and multi-center Post-Market Follow-up (PMCF) study design. HFOV treatment will be evaluated by assessing ventilation and oxygenation variables, and safety will be evaluated by documentation of device related adverse events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rescue High Frequency Oscillatory Ventilation in Newborns Who Do Not Respond to Conventional Ventilation

NCT02752438

Acute Mechanical Ventilatory Failure

UNKNOWN

NHFOV Versus NCPAP to Prevent Exubation Failure

NCT01852916

Respiratory Distress Syndrome

SUSPENDED NA

Evaluation of Prolonged Apnea Supported by High Frequency Non-invasive Ventilation.

NCT02712190

Non-invasive Ventilation High-frequency Ventilation Healthy Volunteer +1 more

UNKNOWN NA

The Difference Between Non-invasive High-frequency Oscillatory Ventilation and Non-invasive Continuous Airway Pressure Ventilation in COVID-19 With Acute Hypoxemia

NCT05706467

COVID-19 Pneumonia Non-invasive Ventilation

UNKNOWN NA

Effect of Noninvasive High Frequency Oscillatory Ventilation on Improving CO2 Clearance in COPD Patients

NCT05721833

COPD Exacerbation Non-invasive Ventilation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate the safety and performance of HFOV modes of the Servo-n ventilator in neonates and infants. This is a prospective, observational, single-arm (i.e., non-controlled) and multi-center PMCF study in neonates and infants between 0.3 to 8 kg. All study procedures are within each hospital's routine clinical practice.The primary endpoints includes variables which are routinely used per clinical practice for assessing the status of patient's ventilation and oxygenation, respectively. Secondary endpoints are used to evaluate safety of Servo-n HFOV during its use by assessing rates of adverse event/ device deficiencies related to the Servo-n HFOV device, and by assessing rates of mortality, Bronchopulmonary Dysplasia (BPD) and Retinopathy at Intensive Care Unit (ICU) discharge. Data collection will take place up to 24 hours prior to HFOV treatment, during HFOV and up to ICU discharge. Additional general data such as ventilator settings, reasons for initiating/terminating HFOV treatment and demographics will also be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elective HFOV for Respiratory Failure in Neonates/Infants Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Servo-n HFOV treatment

As this study is single-armed (non-controlled), all patients in this study receive the same treatment, i.e. Servo-n HFOV treatment. There are however two subgroups, elective HFOV and rescue HFOV treatment

Servo-n HFOV modes

Intervention Type DEVICE

Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Servo-n HFOV modes

Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of written informed consent by the patient's legally designated representative(s) (may be obtained as deferred consent up to 24 hours after HFOV initiation: valid for both elective and rescue HFOV patients)
* Patients eligible for HFOV ventilation with Servo-n:

* Patient is either switched from conventional mechanical ventilation or HFOV with other device to Servo-n HFOV based on clinicians judgement (rescue HFOV). Note: the reason for the switch has to be that the patient failed to oxygenate or ventilate adequately with CMV or the other HFOV device

; OR
* Patient was prior without or with any type of non-invasive respiratory support and is put on invasive HFOV treatment based on clinicians judgement (elective HFOV)
* Patient has not already been on HFOV in a previous episode, unless the etiology of respiratory failure has changed during the same hospitalisation. For example, initial HFOV treatment for RDS, second HFOV episode of NARDS of any etiology (will be enrolled as a new patient case). NOTE1: When a patient failed weaning on conventional ventilation within 6 hours, requiring to be put back on HFOV it will be counted as one HFOV episode (weaning failure) NOTE2: When a patient is temporarily put on conventional ventilation for transport or a surgical intervention, and will be put back to HFOV afterwards, it will be counted as one HFOV episode (HFOV paused).
* Patient has a body weight from 0.3 to 8.0 kg

Exclusion Criteria

* Diagnosis of congenital diaphragmatic hernia
* Severe cardiac anomaly expected to need corrective surgery or catheter-based intervention within 30 days from birth
* Cyanotic heart disease
* Intracranial hemorrhage, Grade III or IV
* Congenital malformations with the exception of isolated lung hypoplasia
* Persistent pulmonary hypertension (PPHN) with a documented shunt on the level of the foramen ovale
* Bronchopulmonary Dysplasia (BPD) /Chronic Lung Disease (CLD)

Eligible Sex

ALL

Accepts Healthy Volunteers

No